

Nitric oxide pathway and phosphodiesterase inhibitors

Journal of the American College of Cardiology

43, S68-S72

DOI: [10.1016/j.jacc.2004.02.031](https://doi.org/10.1016/j.jacc.2004.02.031)

Citation Report

#	ARTICLE	IF	CITATIONS
1	Pulmonary arterial hypertension: building a better mouse trap for 2010. <i>Drug Discovery Today: Therapeutic Strategies</i> , 2004, 1, 351-359.	0.5	3
2	Severe Pulmonary Hypertension in COPD. <i>Chest</i> , 2005, 127, 1480-1482.	0.8	50
3	Effects of Nicorandil on Monocrotaline-Induced Pulmonary Arterial Hypertension in Rats. <i>Journal of Cardiovascular Pharmacology</i> , 2005, 46, 452-458.	1.9	34
5	Efficacy of Acute Inhalation of Nitric Oxide in Patients With Primary Pulmonary Hypertension Using Chronic Use of Continuous Epoprostenol Infusion. <i>Circulation Journal</i> , 2005, 69, 335-338.	1.6	6
6	Chronic sickle cell lung disease: new insights into the diagnosis, pathogenesis and treatment of pulmonary hypertension. <i>British Journal of Haematology</i> , 2005, 129, 449-464.	2.5	115
7	Phosphodiesterase 5 Inhibition in Chronic Heart Failure and Pulmonary Hypertension. <i>American Journal of Cardiology</i> , 2005, 96, 47-51.	1.6	162
9	Long-term therapy of interferon-alpha induced pulmonary arterial hypertension with different PDE-5 inhibitors: a case report. <i>Cardiovascular Ultrasound</i> , 2005, 3, 26.	1.6	29
10	Effect of steroid pulse therapy on mixed connective tissue disease with pulmonary arterial hypertension. <i>Annals of the Rheumatic Diseases</i> , 2005, 64, 1236-1237.	0.9	15
11	Prostanoids and Phosphodiesterase Inhibitors in Experimental Pulmonary Hypertension. <i>Current Topics in Developmental Biology</i> , 2005, 67, 251-284.	2.2	9
12	Drug Insight: endothelin-receptor antagonists for pulmonary arterial hypertension in systemic rheumatic diseases. <i>Nature Clinical Practice Rheumatology</i> , 2005, 1, 93-101.	3.2	16
13	Developmental Expression of Vasoactive and Growth Factors in Human Lung. Role in Pulmonary Vascular Resistance Adaptation at Birth. <i>Pediatric Research</i> , 2005, 57, 21R-25R.	2.3	26
14	Advances in the Medical Treatment of Pulmonary Hypertension. <i>Kidney and Blood Pressure Research</i> , 2005, 28, 311-324.	2.0	4
15	Sildenafil citrate and sildenafil nitrate (NCX 911) are potent inhibitors of superoxide formation and gp91 ^{phox} expression in porcine pulmonary artery endothelial cells. <i>British Journal of Pharmacology</i> , 2005, 146, 109-117.	5.4	71
16	Sildenafil Citrate Therapy for Pulmonary Arterial Hypertension. <i>New England Journal of Medicine</i> , 2005, 353, 2148-2157.	27.0	2,237
17	Management of the Pediatric Postoperative Cardiac Surgery Patient. <i>Critical Care Nursing Clinics of North America</i> , 2005, 17, 405-416.	0.8	16
18	Inhaled tolafentrine reverses pulmonary vascular remodeling via inhibition of smooth muscle cell migration. <i>Respiratory Research</i> , 2005, 6, 128.	3.6	34
19	Effects of Intravenous Nesiritide on Pulmonary Vascular Hemodynamics in Pulmonary Hypertension. <i>Journal of Cardiac Failure</i> , 2005, 11, 425-431.	1.7	34
20	Cold hands–strained heart? Advances in the management of Raynaud's phenomenon and pulmonary hypertension. <i>Arthritis Research</i> , 2005, 7, 126.	2.0	3

#	ARTICLE	IF	CITATIONS
21	NOS2 polymorphisms associated with the susceptibility to pulmonary arterial hypertension with systemic sclerosis: contribution to the transcriptional activity. <i>Arthritis Research and Therapy</i> , 2006, 8, R104.	3.5	39
22	Present and Future Treatment Strategies for Pulmonary Arterial Hypertension. <i>Treatments in Respiratory Medicine</i> , 2006, 5, 271-282.	1.4	8
23	Sildenafil citrate for the treatment of pulmonary arterial hypertension. <i>Expert Opinion on Pharmacotherapy</i> , 2006, 7, 825-828.	1.8	8
24	Oral Sildenafil in Infants With Persistent Pulmonary Hypertension of the Newborn: A Pilot Randomized Blinded Study. <i>Pediatrics</i> , 2006, 117, 1077-1083.	2.1	291
25	Differential Effects of Phosphodiesterase-5 Inhibitors on Hypoxic Pulmonary Vasoconstriction and Pulmonary Artery Cytokine Expression. <i>Annals of Thoracic Surgery</i> , 2006, 81, 272-278.	1.3	54
26	Nitric oxide-dependent vasorelaxation induced by extractive solutions and fractions of <i>Maytenus ilicifolia</i> Mart ex Reissek (Celastraceae) leaves. <i>Journal of Ethnopharmacology</i> , 2006, 104, 328-335.	4.1	27
27	Treatment of pulmonary hypertension with selective pulmonary vasodilators. <i>Current Opinion in Anaesthesiology</i> , 2006, 19, 88-95.	2.0	20
28	Effects of long-term vardenafil treatment on the development of fibrotic plaques in a rat model of Peyronie's disease. <i>BJU International</i> , 2006, 97, 625-633.	2.5	119
29	Sildenafil: from angina to erectile dysfunction to pulmonary hypertension and beyond. <i>Nature Reviews Drug Discovery</i> , 2006, 5, 689-702.	46.4	471
30	A Novel Approach Incorporating Sildenafil in the Management of Symptomatic Neonates with Ebstein's Anomaly. <i>Pediatric Cardiology</i> , 2006, 27, 614-617.	1.3	8
31	Effect of oral sildenafil citrate on intraoperative hemodynamics in patients with pulmonary hypertension undergoing valvular heart surgery. <i>Journal of Thoracic and Cardiovascular Surgery</i> , 2006, 132, 1420-1425.	0.8	43
32	Paullinia pinnata Extracts Rich in Polyphenols Promote Vascular Relaxation via Endothelium-dependent Mechanisms. <i>Journal of Cardiovascular Pharmacology</i> , 2006, 47, 599-608.	1.9	44
33	Medical Therapies for Chronic Thromboembolic Pulmonary Hypertension: An Evolving Treatment Paradigm. <i>Proceedings of the American Thoracic Society</i> , 2006, 3, 594-600.	3.5	90
34	Abnormal pulmonary vascular responses in patients registered with a systemic autoimmunity database: Pulmonary Hypertension Assessment and Screening Evaluation using stress echocardiography (PHASE-I). <i>European Journal of Echocardiography</i> , 2006, 7, 439-446.	2.3	71
35	Sildenafil for pulmonary arterial hypertension. <i>Future Cardiology</i> , 2006, 2, 137-143.	1.2	2
36	Hemolytic Anemia Associated Pulmonary Hypertension. , 2006, , 170-187.		4
37	Right Ventricular Diastolic Dysfunction and the Acute Effects of Sildenafil in Pulmonary Hypertension Patients. <i>Chest</i> , 2007, 132, 11-17.	0.8	138
38	The erectile endothelial dysfunction nexus: new opportunities for cardiovascular risk prevention. <i>Nature Clinical Practice Cardiovascular Medicine</i> , 2007, 4, 263-273.	3.3	55

#	ARTICLE	IF	CITATIONS
39	The Impact of Pulmonary Arterial Hypertension on Idiopathic Pulmonary Fibrosis. <i>Chest</i> , 2007, 131, 641-643.	0.8	18
40	Pulmonary Arterial Hypertension. <i>Critical Care Nursing Quarterly</i> , 2007, 30, 20-41.	0.8	18
41	Use of Sildenafil in Heart Transplant Recipients With Pulmonary Hypertension May Prevent Right Heart Failure. <i>Transplantation Proceedings</i> , 2007, 39, 2850-2852.	0.6	36
42	Cardiac Effects of Pulmonary Disease. <i>Veterinary Clinics of North America - Small Animal Practice</i> , 2007, 37, 949-962.	1.5	21
44	Sildenafil: A recent advance in the treatment of pulmonary arterial hypertension. <i>British Journal of Cardiac Nursing</i> , 2007, 2, 61-68.	0.1	0
45	AMLODIPINE PREVENTS MONOCROTALINE-INDUCED PULMONARY ARTERIAL HYPERTENSION AND PROLONGS SURVIVAL IN RATS INDEPENDENT OF BLOOD PRESSURE LOWERING. <i>Clinical and Experimental Pharmacology and Physiology</i> , 2007, 34, 594-600.	1.9	23
46	Daily Administration of Phosphodiesterase Type 5 Inhibitors for Urological and Nonurological Indications. <i>European Urology</i> , 2007, 52, 990-1005.	1.9	49
47	Management of Pulmonary Arterial Hypertension Associated with Congenital Systemic-to-Pulmonary Shunts and Eisenmenger's Syndrome. <i>Drugs</i> , 2008, 68, 1049-1066.	10.9	153
48	Expression and function of soluble guanylate cyclase in pulmonary arterial hypertension. <i>European Respiratory Journal</i> , 2008, 32, 881-891.	6.7	216
49	Synergy between Natriuretic Peptides and Phosphodiesterase 5 Inhibitors Ameliorates Pulmonary Arterial Hypertension. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2008, 178, 861-869.	5.6	59
50	Advances in therapies for pediatric pulmonary arterial hypertension. <i>Expert Review of Respiratory Medicine</i> , 2009, 3, 265-282.	2.5	5
51	Preserved pulmonary vasodilative properties of aerosolized brain natriuretic peptide. <i>Pulmonary Pharmacology and Therapeutics</i> , 2009, 22, 548-553.	2.6	1
52	Cyclic GMP-Hydrolyzing Phosphodiesterases. <i>Handbook of Experimental Pharmacology</i> , 2009, , 367-408.	1.8	33
53	Long-Term Ambrisentan Therapy for the Treatment of Pulmonary Arterial Hypertension. <i>Journal of the American College of Cardiology</i> , 2009, 54, 1971-1981.	2.8	227
54	Riociguat for treatment of pulmonary hypertension. <i>Clinical Research in Cardiology Supplements</i> , 2010, 5, 16-18.	2.0	3
55	Sequence Variants in <i>BMPR2</i> and Genes Involved in the Serotonin and Nitric Oxide Pathways in Idiopathic Pulmonary Arterial Hypertension and Chronic Thromboembolic Pulmonary Hypertension: Relation to Clinical Parameters and Comparison with Left Heart Disease. <i>Respiration</i> , 2010, 79, 279-287.	2.6	27
56	Clinical Year in Review I: Interstitial Lung Disease, Pulmonary Vascular Disease and Venous Thromboembolism, Diagnostic Imaging, and Lung Cancer. <i>Proceedings of the American Thoracic Society</i> , 2010, 7, 297-304.	3.5	0
57	The Extracellular Signal-Regulated Kinase Is Involved in the Effects of Sildenafil on Pulmonary Vascular Remodeling. <i>Cardiovascular Therapeutics</i> , 2010, 28, 23-29.	2.5	15

#	ARTICLE	IF	CITATIONS
58	Riociguat for the treatment of pulmonary hypertension. <i>Expert Opinion on Investigational Drugs</i> , 2011, 20, 567-576.	4.1	81
59	Sildenafil and Bosentan Improve Arterial Oxygenation During Acute Hypoxic Exercise: A Controlled Laboratory Trial. <i>Wilderness and Environmental Medicine</i> , 2011, 22, 211-221.	0.9	21
60	Tadalafil for the treatment of pulmonary arterial hypertension. <i>Expert Review of Respiratory Medicine</i> , 2011, 5, 315-328.	2.5	7
61	Pulmonary complications in cirrhosis. <i>Current Opinion in Organ Transplantation</i> , 2011, 16, 281-288.	1.6	26
62	Tadalafil: A Long-Acting Phosphodiesterase-5 Inhibitor for the Treatment of Pulmonary Arterial Hypertension. <i>Clinical Therapeutics</i> , 2011, 33, 993-1004.	2.5	34
63	Sildenafil therapy for neonatal and childhood pulmonary hypertensive vascular disease. <i>Cardiology in the Young</i> , 2011, 21, 187-193.	0.8	41
64	Does the Outcome Justify an Oral-First Treatment Strategy for Management of Pulmonary Arterial Hypertension?. <i>Chest</i> , 2011, 140, 697-705.	0.8	4
65	Recent advances and future perspectives in therapeutic strategies for pulmonary arterial hypertension. <i>Journal of Cardiology</i> , 2012, 60, 344-349.	1.9	22
66	The Soluble Guanylate Cyclase Stimulator Riociguat Ameliorates Pulmonary Hypertension Induced by Hypoxia and SU5416 in Rats. <i>PLoS ONE</i> , 2012, 7, e43433.	2.5	100
67	High inter-individual variability of vardenafil pharmacokinetics in patients with pulmonary hypertension. <i>European Journal of Clinical Pharmacology</i> , 2013, 69, 197-207.	1.9	7
68	Oral Therapies for Pulmonary Arterial Hypertension. <i>Clinics in Chest Medicine</i> , 2013, 34, 811-824.	2.1	6
69	Signal Transduction in the Development of Pulmonary Arterial Hypertension. <i>Pulmonary Circulation</i> , 2013, 3, 278-293.	1.7	69
70	The First Keystone Symposia Conference on Pulmonary Vascular Disease and Right Ventricular Dysfunction: Current Concepts and Future Therapies. <i>Pulmonary Circulation</i> , 2013, 3, 275-277.	1.7	2
71	Management of chronic thromboembolic pulmonary hypertension: current status and emerging options. <i>Clinical Practice (London, England)</i> , 2013, 10, 345-357.	0.1	2
72	Pulmonary Hypertension and Cardiopulmonary Exercise in Heart Failure. <i>Pulse</i> , 2013, 1, 143-151.	1.9	2
73	Structural and functional prevention of hypoxia-induced pulmonary hypertension by individualized exercise training in mice. <i>American Journal of Physiology - Lung Cellular and Molecular Physiology</i> , 2014, 306, L986-L995.	2.9	31
74	Efficacy and safety of sildenafil treatment in pulmonary arterial hypertension: A systematic review. <i>Respiratory Medicine</i> , 2014, 108, 531-537.	2.9	42
75	Thrombosis, platelets, microparticles and PAH: more than a clot. <i>Drug Discovery Today</i> , 2014, 19, 1230-1235.	6.4	42

#	ARTICLE	IF	CITATIONS
76	The impact of drug-drug interactions on pulmonary arterial hypertension therapy. <i>Pulmonary Pharmacology and Therapeutics</i> , 2014, 28, 1-8.	2.6	24
77	Riociguat: A Novel Therapeutic Option for Pulmonary Arterial Hypertension and Chronic Thromboembolic Pulmonary Hypertension. <i>Canadian Journal of Cardiology</i> , 2014, 30, 1233-1240.	1.7	12
79	Acute vasodilator response to vardenafil and clinical outcome in patients with pulmonary hypertension. <i>European Journal of Clinical Pharmacology</i> , 2015, 71, 1165-1173.	1.9	2
80	Liposomal Aerosols of Nitric Oxide (NO) Donor as a Long-Acting Substitute for the Ultra-Short-Acting Inhaled NO in the Treatment of PAH. <i>Pharmaceutical Research</i> , 2016, 33, 1696-1710.	3.5	25
81	Sildenafil citrate therapy for secondary pulmonary arterial hypertension due to chronic obstructive lung disease. <i>The Egyptian Journal of Chest Diseases and Tuberculosis</i> , 2016, 65, 805-809.	0.2	4
82	Guanylate cyclase stimulators for pulmonary hypertension. <i>The Cochrane Library</i> , 2016, 2016, CD011205.	2.8	14
83	Sildenafil reduces signs of oxidative stress in pulmonary arterial hypertension: Evaluation by fatty acid composition, level of hydroxynonenal and heart rate variability. <i>Redox Biology</i> , 2016, 7, 48-57.	9.0	31
84	Quantitative Dual-Energy Computed Tomography Supports a Vascular Etiology of Smoking-induced Inflammatory Lung Disease. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2016, 193, 652-661.	5.6	77
85	Oral Tadalafil in Children with Pulmonary Arterial Hypertension. <i>Drug Research</i> , 2016, 66, 7-10.	1.7	18
86	Advances in treatment of pulmonary arterial hypertension: patent review. <i>Expert Opinion on Therapeutic Patents</i> , 2017, 27, 907-918.	5.0	13
87	Cardiopulmonary protective effects of the selective FXR agonist obeticholic acid in the rat model of monocrotaline-induced pulmonary hypertension. <i>Journal of Steroid Biochemistry and Molecular Biology</i> , 2017, 165, 277-292.	2.5	24
88	3,7-Bis(2-hydroxyethyl)icaritin, a potent inhibitor of phosphodiesterase-5, prevents monocrotaline-induced pulmonary arterial hypertension via NO/cGMP activation in rats. <i>European Journal of Pharmacology</i> , 2018, 829, 102-111.	3.5	14
89	Sildenafil, a phosphodiesterase-5 inhibitor, offers protection against carbon tetrachloride-induced hepatotoxicity in rat. <i>Journal of Basic and Clinical Physiology and Pharmacology</i> , 2018, 29, 29-35.	1.3	7
90	Current Trends and Future Perspectives in the Treatment of Pulmonary Arterial Hypertension. <i>Current Problems in Cardiology</i> , 2018, 43, 191-216.	2.4	4
91	Phosphodiesterase 3 and 4 Inhibition: Facing a Bright Future in Asthma Control. , 0, , .		6
92	The role of platelets in the development and progression of pulmonary arterial hypertension. <i>Advances in Medical Sciences</i> , 2018, 63, 312-316.	2.1	22
93	Phosphodiesterase 5 inhibitors for pulmonary hypertension. <i>The Cochrane Library</i> , 2019, 2019, CD012621.	2.8	70
94	Sildenafil for Pulmonary Arterial Hypertension. <i>American Journal of Therapeutics</i> , 2019, 26, e520-e526.	0.9	39

#	ARTICLE	IF	CITATIONS
95	Urantide improves the structure and function of right ventricle as determined by echocardiography in monocrotaline-induced pulmonary hypertension rat model. <i>Clinical Rheumatology</i> , 2019, 38, 29-35.	2.2	11
96	Established and emerging therapeutic uses of PDE type 5 inhibitors in cardiovascular disease. <i>British Journal of Pharmacology</i> , 2020, 177, 5467-5488.	5.4	65
97	Functional implications of vascular endothelium in regulation of endothelial nitric oxide synthesis to control blood pressure and cardiac functions. <i>Life Sciences</i> , 2020, 259, 118377.	4.3	23
98	IRAG1 Deficient Mice Develop PKG1 ^β Dependent Pulmonary Hypertension. <i>Cells</i> , 2020, 9, 2280.	4.1	7
99	Inhibition of eNOS by L-NAME resulting in rat hind limb developmental defects through PFKFB3 mediated angiogenic pathway. <i>Scientific Reports</i> , 2020, 10, 16754.	3.3	11
100	The Effect of Sildenafil on Selenite-Induced Cataract in Rats. <i>Current Eye Research</i> , 2020, 45, 1082-1088.	1.5	1
101	Phosphodiesterase-5 Inhibitors in Pulmonary Arterial Hypertension. , 0, , 105-125.		1
102	Pulmonary Hypertension: Novel Pathways and Emerging Therapies Inhibitors of cGMP and cAMP Metabolism. <i>Handbook of Experimental Pharmacology</i> , 2013, , 513-529.	1.8	3
103	Inhibition of MRP4 prevents and reverses pulmonary hypertension in mice. <i>Journal of Clinical Investigation</i> , 2011, 121, 2888-2897.	8.2	83
104	Riociguat versus sildenafil on hypoxic pulmonary vasoconstriction and ventilation/perfusion matching. <i>PLoS ONE</i> , 2018, 13, e0191239.	2.5	15
105	Pulmonary Arterial Hypertension in Women. <i>Methodist DeBakey Cardiovascular Journal</i> , 2021, 13, 224.	1.0	14
106	Fabrication and Characterization of Sildenafil Citrate Loaded Transfersomes as a Carrier for Transdermal Drug Delivery. <i>Pharmacy & Pharmacology International Journal</i> , 2017, 5, .	0.2	9
107	Drug Interactions in Pulmonary Arterial Hypertension and Their Implications. <i>European Cardiology Review</i> , 2009, 5, 46.	2.2	2
108	Treatment Selection in Pulmonary Arterial Hypertension: Phosphodiesterase Type 5 Inhibitors versus Soluble Guanylate Cyclase Stimulator. <i>European Cardiology Review</i> , 2018, 13, 35.	2.2	12
109	The biofilm inhibition activity of a NO donor nanosilica with enhanced antibiotics action. <i>International Journal of Pharmaceutics</i> , 2021, 610, 121220.	5.2	14
111	Pulmonary Arterial Hypertension. , 2006, , 543-548.		0
112	VASCULAR DISEASE. , 2006, , 399-413.		0
113	Survival Patterns Without Cardiac Surgery or Interventional Catheterization: A Narrowing Base. , 2009, , 25-67.		4

#	ARTICLE	IF	CITATIONS
114	PULMONARY ARTERIAL HYPERTENSION. , 2009, , 401-415.		0
115	Pulmonary Arterial Hypertension in Pregnancy. , 2009, , 285-312.		0
116	Treatment of severe pulmonary hypertension with sildenafil in a heart transplant candidate for advanced heart failure. <i>Cor Et Vasa</i> , 2009, 51, 279-281.	0.1	1
117	Roles of Endothelium-Derived Vasoactive and Mitogenic Factors in the Development of Chronic Hypoxia-Mediated Pulmonary Hypertension. , 2011, , 695-711.		0
118	Selective Pulmonary Vasodilators. , 2015, , 809-836.		0
119	8th Asian PAD Workshop. <i>Annals of Vascular Diseases</i> , 2017, 10, 449-458.	0.5	0
120	Sildenafil Administration in Early Onset Intrauterine Growth Restriction. <i>International Journal of Pregnancy & Child Birth</i> , 2017, 3, .	0.1	0
121	Phosphodiesterase-5 Inhibitors. <i>Handbook of Experimental Pharmacology</i> , 2013, 218, 229-255.	1.8	5
122	Pulmonary Hypertension: Novel Pathways and Emerging Therapies Inhibitors of cGMP and cAMP Metabolism. <i>Handbook of Experimental Pharmacology</i> , 2013, 218, 513-529.	1.8	2
123	Giant, dissecting, high-pressure pulmonary artery aneurysm: case report of a 1-year natural course. <i>Texas Heart Institute Journal</i> , 2005, 32, 589-94.	0.3	26
124	Role of NO-cGMP-PKG axis in pulmonary arterial hypertension. <i>Folia Pharmacologica Japonica</i> , 2022, 157, 221-225.	0.2	1
125	Clinical significance of pulmonary hypertension in interstitial lung disease: A consensus statement from the Pulmonary Vascular Research Institute's innovative drug development initiative"Group 3 pulmonary hypertension. <i>Pulmonary Circulation</i> , 2022, 12, .	1.7	15
126	A systematic review of clinical study evidence for pulmonary vasodilator therapy following surgery with cardiopulmonary bypass in children with CHD. <i>Cardiology in the Young</i> , 2022, 32, 1373-1390.	0.8	0
127	Utility of NO and H2S donating platforms in managing COVID-19: Rationale and promise. <i>Nitric Oxide - Biology and Chemistry</i> , 2022, , .	2.7	4
128	Computational models of ventricular mechanics and adaptation in response to right-ventricular pressure overload. <i>Frontiers in Physiology</i> , 0, 13, .	2.8	3
129	Biochemical markers in the management of pulmonary hypertension. <i>Swiss Medical Weekly</i> , 0, , .	1.6	3
130	Pretreatment with tadalafil attenuates cardiotoxicity induced by combretastatin A4 disodium phosphate in rats. <i>Journal of Toxicologic Pathology</i> , 2023, 36, 151-158.	0.7	1
131	Effects of acute phosphodiesterase type 5 inhibition on skeletal muscle interstitial PO2 during contractions and recovery. <i>Nitric Oxide - Biology and Chemistry</i> , 2024, 142, 16-25.	2.7	0